Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Metastatic cancer
Stage/Subtype:  brain metastases
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 48 for your search:
Start Over
Stereotactic Radiosurgery Compared to Observation in Treating Patients with Brain Metastases
Phase: Phase III
Type: Treatment
Age: 3 and over
Trial IDs: 2009-0381, NCI-2011-00542, NCT00950001
Stereotactic Radiosurgery or Whole Brain Radiation Therapy in Treating Patients with Newly Diagnosed Non-melanoma Brain Metastases
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 2011-0884, NCI-2014-02058, NCI-2012-00850, NCT01592968
Stereotactic Radiosurgery in Treating Patients with Large Brain Metastases
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 8312, NCI-2013-00845, CASE8312, NCT01843413
Radiosurgery Before Surgery in Treating Patients with Brain Metastases That Can be Removed by Surgery
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CASE 7312, NCI-2013-00644, NCT01891318
Everolimus, Trastuzumab, and Vinorelbine Tartrate in Treating Patients With Progressive HER2-Positive Breast Cancer and Brain Metastases
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 and over
Trial IDs: LCCC 1025, NCI-2013-01079, 11-0242, NCT01305941
Hippocampal-Avoiding Whole-Brain Radiotherapy with Simultaneous-Integrated Boost Intensity-Modulated Radiation Therapy in Treating Patients with Brain Metastases
Phase: Phase II
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: STU 042011-050, NCI-2015-01675, NCI-2014-01736, NCI-2014-02008, NCT01414738
Neratinib, Capecitabine, and Trastuzumab in Treating Patients with HER2-Positive Breast Cancer That Has Spread to the Brain
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-344, NCI-2012-00255, TBCRC 022, NCT01494662
Whole-Brain Radiation Therapy with or without Lapatinib Ditosylate in Treating Patients with Brain Metastasis from HER2-Positive Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: RTOG 1119, NCI-2012-01977, CDR0000735353, NCT01622868
Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer and High Dose Aldesleukin in Treating Patients With Metastatic Melanoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: MCC #16992, NCI-2012-01379, NCT01659151
Dabrafenib and Stereotactic Radiosurgery in Treating Patients With Melanoma and Brain Metastases
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CC # 12857, NCI-2012-02214, NCT01721603
Bevacizumab in Pats w/ Recurrent ST Brain Metas who have Failed Whole Brain Radiation Therapy
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: NU 12C06, NCI-2013-00448, STU00080404, NCT01898130
Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 116521, NCI-2014-01364, NCT01978236
Radiosurgery in Treating Patients With Brain Metastases
Phase: Phase II
Type: Treatment
Age: Over 18
Trial IDs: 1306012291, NCI-2013-01986, NCT02005614
Study to Evaluate Treatment of Dabrafenib Plus Trametinib in Subjects With BRAF Mutation-Positive Melanoma That Has Metastasized to the Brain
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 117277, NCI-2014-01207, NCT02039947
Dacomitinib in Treating Patients with Progressive Brain Metastases
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UCSD 130418, NCI-2014-00818, 130418, DP01-WS2043189, NCT02047747
PET-Adjusted Intensity Modulated Radiation Therapy and Combination Chemotherapy in Treating Patients with Stage II-IV Non-small Cell Lung Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2013-252, NCI-2014-00216, NCT02073968
Pembrolizumab in Treating Patients with Metastatic Melanoma or Non-small Cell Lung Cancer and Untreated Brain Metastases
Phase: Phase II
Type: Treatment
Age: Over 18
Trial IDs: 1401013290, NCI-2015-02019, PN027, NCT02085070
Ipilimumab Induction in Treating Patients with Melanoma Metastatic to the Brain Undergoing Stereotactic Radiosurgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UMCC 2013.114, NCI-2014-01215, 2013.114, HUM00082134, NCT02097732
Stereotactic Radiosurgery and Ipilimumab in Treating Patients With Metastatic Melanoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: OSU-12182, NCI-2014-00381, CA184-236, NCT02107755
Cabozantinib S-malate with or without Trastuzumab in Treating Patients with Breast Cancer and Brain Metastases
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 14-359, NCI-2014-02365, NCT02260531
A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15450, NCI-2015-00514, 2014-004010-28, I3Y-MC-JPBO, NCT02308020
Pegylated Irinotecan NKTR 102 in Treating Patients with Refractory Brain Metastasis from Non-small Cell Lung Cancer or Small Cell Lung Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: LUN0067, NCI-2014-02101, 350, 351, NCT02312622
Start Over